{
  "report_rows": [
    {
      "kpi": "Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.43B vs. cons $3.37B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.27 vs. cons $1.24",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EBITDA",
      "prediction": "IN-LINE",
      "answer": "pred ~$272M vs. cons $270M",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Non-GAAP diluted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.30 midpoint vs. cons $5.32 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EBITDA growth",
      "prediction": "LOWER",
      "answer": "guide ~5% vs. cons 6% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Value-creation operating-income run rate",
      "prediction": "UNCHANGED",
      "answer": "guide ~$125M vs. cons $125M (year-end 2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.4,
  "day5_path": "FADE",
  "day5_rationale": "A modest Q2 beat should initially lift the stock, but an unchanged ~$5.30 FY2026 EPS midpoint after predicted first-half EPS of ~$2.59 implies only ~$2.71 for the second half versus the prior consensus requirement of ~$2.76. That implicit out-period reduction should limit estimate revisions and fade most of the day-1 gain.",
  "day5_confidence": "MEDIUM"
}